Fate Therapeutic Stock Price, News & Analysis

Fate Therapeutics reported on November 3, 2022, positive FDA feedback for its FT516 program under RMAT designation, supporting its iPSC product platform for aggressive lymphomas. The company is conducting multiple Phase 1 studies, including FT596 for r/r B-cell lymphoma and FT576 for multiple myeloma. The third quarter of 2022 saw total revenue of $15 million against R&D expenses of $79.8 million, reflecting significant investment in product development. Cash and investments totaled $519.1 million, providing a solid financial foundation for ongoing clinical trials.

Fate Therapeutics announced that fourteen presentations have been accepted for the 64th American Society of Hematology Annual Meeting from December 10-13, 2022. Key highlights include initial Phase 1 clinical data for the FT576 CAR NK cell targeting BCMA and FT819 CAR T-cell targeting CD19. The company will also present preclinical data for FT555 and discuss innovative methods to enhance the efficacy of off-the-shelf iPSC-derived cell therapies, such as eliminating patient conditioning. The ASH presentations aim to showcase advancements in Fate's iPSC product platform.

Fate Therapeutics (NASDAQ: FATE) announced a conference call and live audio webcast scheduled for November 3, 2022 at 5:00 PM ET to discuss its third quarter 2022 financial results and provide a corporate update. This event reflects the company's ongoing commitment to transparency with its investors. The call will be accessible via registration, and an archived version will be available on the company's website shortly after the event.

Fate Therapeutics, Inc. (NASDAQ: FATE) has announced its participation in the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, scheduled for November 8-12, 2022. The company will present clinical and preclinical data on its induced pluripotent stem cell (iPSC) product platform, including interim Phase I results of FT538, FT516, and FT500 therapies targeting advanced solid tumors. These presentations aim to demonstrate the efficacy of engineered cell therapies designed to enhance treatment outcomes for cancer patients.

Fate Therapeutics (NASDAQ: FATE) announced its participation in several investor conferences in September 2022. The company will host 1x1 meetings at Citi’s 17th Annual BioPharma Conference on September 8, and participate in a fireside chat at the Wells Fargo 2022 Healthcare Conference on September 9 and the Morgan Stanley 20th Annual Global Healthcare Conference on September 12. Fate will also join fireside chats at the Baird 2022 Global Health Conference and H.C. Wainwright 24th Annual Global Investment Conference on September 13. Webcasts will be available on the company's website.

Fate Therapeutics (NASDAQ: FATE) has announced significant progress in its clinical research with the publication of preclinical study results on TCR^-CAR⁺ iPSC-derived CD8αβ T cells, demonstrating robust anti-tumor responses in systemic leukemia models. These findings support the ongoing Phase 1 study of FT819, a first-of-its-kind iPSC-derived T-cell therapy, aimed at treating relapsed/refractory B-cell malignancies. The research, conducted with Memorial Sloan Kettering Cancer Center, highlights the potential for off-the-shelf cancer immunotherapies that overcome manufacturing challenges associated with traditional therapies.

Fate Therapeutics reported its Q2 2022 results, highlighting ongoing clinical trials for its product candidates targeting aggressive B-cell lymphoma and solid tumors. The company has initiated enrollment in multiple studies, including FT596+R for relapsed/refractory B-cell lymphoma and FT536 for solid tumors. With $580.8 million in cash and $18.5 million in revenue for the quarter, Fate is actively expanding collaborations with Janssen and ONO. R&D expenses totaled $81.3 million, reflecting investment in its innovative therapies.

Fate Therapeutics (NASDAQ: FATE) announced a conference call on August 3, 2022, at 5:00 PM ET to discuss its Q2 2022 financial results and provide a corporate update. The call can be accessed via phone or a live audio webcast available on the Company’s website. Fate Therapeutics focuses on developing advanced cellular immunotherapies for cancer patients, utilizing its proprietary induced pluripotent stem cell (iPSC) technology. The Company aims to establish a leadership position in the clinical development of universal, off-the-shelf cell products.

Fate Therapeutics (NASDAQ: FATE) has appointed Brian T. Powl as Chief Commercial Officer, bringing extensive experience in commercial leadership for hematologic malignancies. Powl previously led the global commercial strategy for CAR T-cell therapies at Celgene. His expertise is expected to enhance Fate's late-stage clinical development and product launch pathways for off-the-shelf cellular immunotherapies. Powl received options for 70,000 shares and 45,000 restricted stock units, both vesting over four years, aligning his incentives with company performance.